伊伐布雷定在心力衰竭管理中的应用：一项批判性评估。
Ivabradine in Management of Heart Failure: a Critical Appraisal.
作者信息
Orasanu Gabriela, Al-Kindi Sadeer G, Oliveira Guilherme H
机构信息
Advanced Heart Failure and Transplantation Center, Harrington Heart & Vascular Institute, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
出版信息
Curr Heart Fail Rep. 2016 Feb;13(1):60-9. doi: 10.1007/s11897-016-0276-x.
Elevated resting heart rate has been linked to poor outcomes in patients with chronic systolic heart failure. Blockade of funny current channel with ivabradine reduces heart rate without inotropic effects. Ivabradine was recently approved by US Food and Drug Administration for patients with stable, symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≤35 %, who are in sinus rhythm with resting heart rate (HR) ≥ 70 bpm and either are on maximally tolerated doses of beta-blockers, or have a contraindication to beta-blockers. This article will review and evaluate the data supporting the use of ivabradine in patients with HF and explore its mechanisms and physiologic effects.
静息心率升高与慢性收缩性心力衰竭患者的不良预后相关。伊伐布雷定阻断起搏电流通道可降低心率，且无正性肌力作用。最近，美国食品药品监督管理局批准伊伐布雷定用于左心室射血分数（LVEF）≤35%、静息心率（HR）≥70次/分且处于窦性心律、正在服用最大耐受剂量β受体阻滞剂或有β受体阻滞剂禁忌证的稳定、有症状的慢性心力衰竭（HF）患者。本文将回顾和评估支持伊伐布雷定用于HF患者的数据，并探讨其作用机制和生理效应。
Zotero 插件